FDA Issues Draft Guidance for Sponsors and Other Stakeholders on Using Registries as RWD to Support Regulatory Decision-Making | Faegre Drinker Biddle & Reath LLP

The U.S. Food and Drug Administration (FDA) issued its third draft guidance under the Real-World Evidence (RWE) Program on November 29, 2021. In Real-World Data: Assessing Registries to...

Related Keywords

,Program On ,Faegre Drinker Biddle Reath ,Drug Administration ,Faegre Drinker Biddle ,Real World Evidence ,Real World Data ,Assessing Registries ,Support Regulatory Decision Making ,Biological Products ,Federal Food Drug ,Cosmetic Act ,Using Registry Data ,Support Regulatory ,Considerations When Linking ,